Rigel Pharmaceuticals (RIGL) Share-based Compensation (2010 - 2026)

Rigel Pharmaceuticals' Share-based Compensation history runs 16 years deep, the most recent figure standing at $2.7 million for Q4 2025.

• In Q4 2025, Share-based Compensation rose 126.66% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $4.4 million (up 150.55% YoY), while the FY2025 annual figure was $12.7 million, up 19.92% from the prior year.
• Share-based Compensation for Q4 2025 stood at $2.7 million, down from $17.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $17.3 million in Q3 2025, with the low at -$10.3 million in Q4 2024.
• The 5-year median for Share-based Compensation is $769500.0 (2022), against an average of $1.4 million.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 633.16% in 2024, then soared 10849.37% in 2025.
• Rigel Pharmaceuticals' Share-based Compensation stood at $2.3 million in 2021, then soared by 74.43% to $4.1 million in 2022, then slumped by 52.62% to $1.9 million in 2023, then sank by 633.16% to -$10.3 million in 2024, then surged by 126.66% to $2.7 million in 2025.
• Business Quant data shows RIGL's Share-based Compensation at $2.7 million in Q4 2025, $17.3 million in Q3 2025, and $418000.0 in Q2 2025.